Skye Bioscience Inc (SKYE)

Dec 19, 2024, 7:00 AM EST - 4 weeks ago

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Dec 10, 2024, 8:32 AM EST - 5 weeks ago

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Nov 14, 2024, 7:00 AM EST - 2 months ago

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Nov 7, 2024, 10:36 PM EST - 2 months ago

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 2 months ago

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Nov 1, 2024, 7:00 AM EDT - 2 months ago

Skye Bioscience to Announce Third Quarter 2024 Results

Oct 21, 2024, 7:00 AM EDT - 3 months ago

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

Oct 9, 2024, 1:13 PM EDT - 3 months ago

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

RENT SCWO

Sep 4, 2024, 11:26 AM EDT - 4 months ago

Skye: Moving Weight Loss Drugs To The Next Level

Aug 26, 2024, 7:00 AM EDT - 5 months ago

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Aug 23, 2024, 6:45 PM EDT - 5 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 22, 2024, 7:00 AM EDT - 5 months ago

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Aug 21, 2024, 10:00 AM EDT - 5 months ago

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 19, 2024, 11:00 AM EDT - 5 months ago

Investors With Losses In Skye Bioscience Inc Are Urged To Join Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 5 months ago

Skye Bioscience Inc Shareholders Encouraged Be A Part Of Fraud Investigation With The Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 5 months ago

Skye Bioscience Inc Investors Invited To Partake In Fraud Investigation With The Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 5 months ago

Skye Bioscience Inc Shareholders Encouraged To Join In Fraud Investigation With The Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 5 months ago

Skye Bioscience Inc Investors Encouraged To Join In Fraud Investigation With The Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 5 months ago

Skye Bioscience Inc Investors Urged To Participate In Fraud Investigation With The Schall Law Firm

Aug 14, 2024, 12:40 AM EDT - 5 months ago

Skye Bioscience Inc Investors Encouraged To Join Fraud Investigation With The Schall Law Firm

Aug 13, 2024, 2:00 AM EDT - 5 months ago

Skye Bioscience Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm

Aug 9, 2024, 8:30 PM EDT - 5 months ago

Skye Bioscience Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm

Aug 9, 2024, 5:59 PM EDT - 5 months ago

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 8, 2024, 9:30 PM EDT - 5 months ago

Skye Bioscience Inc Investors Can Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 3:30 PM EDT - 5 months ago

Skye Bioscience Inc Investors Are Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 3:30 PM EDT - 5 months ago

Skye Bioscience Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 5, 2024, 10:15 AM EDT - 5 months ago

SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm

Jul 24, 2024, 7:30 AM EDT - 6 months ago

Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity

Jul 24, 2024, 6:00 AM EDT - 6 months ago

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Jul 11, 2024, 7:15 AM EDT - 6 months ago

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

Jul 11, 2024, 7:00 AM EDT - 6 months ago

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Jul 3, 2024, 7:00 AM EDT - 7 months ago

Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

Jul 1, 2024, 7:00 AM EDT - 7 months ago

Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes

Jun 10, 2024, 8:10 AM EDT - 7 months ago

Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session

PERI

Jun 10, 2024, 7:19 AM EDT - 7 months ago

Skye Bioscience to discontinue development of eye disease treatment

Jun 3, 2024, 7:00 AM EDT - 8 months ago

Skye Bioscience to Present at Jefferies Global Healthcare Conference

May 14, 2024, 2:55 PM EDT - 8 months ago

Skye Bioscience (SKYE) CEO on Drug Development